NCT00602862View on ClinicalTrials.gov

Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2012

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Sorafenib

Sorafenib 200 mg 2dd2 po for 4 weeks before surgery

DRUG

111Indium-bevacizumab

100 MBq / 1 mg 111Indium/bevacizumab iv

DRUG

111Indium-cG250

100 MBq / 10 mg 111Indium-cG250 iv

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Center, Nijmegen

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

Radboud University Medical Center

OTHER

NCT00602862 - Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 | Biotech Hunter | Biotech Hunter